Aqua Viva Oral powder Saudo Arabija - anglų - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

aqua viva oral powder

bioveta a.s., czech republic - natrii citras anhydricus, natrii acetas anhydricus, natrii propionas, kalii chloridum, natrii chloridum, kalii dihydrogenophosphas - oral powder - 1.36.4.68.2.98.1.92.3.28 g

NATIVEREMEDIES TRIPLE COMPLEX UT TONIC- ferrum phos, kalii sulph, nat phos. liquid Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

nativeremedies triple complex ut tonic- ferrum phos, kalii sulph, nat phos. liquid

silver star brands - potassium sulfate (unii: 1k573lc5tv) (potassium cation - unii:295o53k152), ferrosoferric phosphate (unii: 91gqh8i5f7) (ferrosoferric phosphate - unii:91gqh8i5f7), sodium phosphate, dibasic (unii: gr686lba74) (phosphate ion - unii:nk08v8k8hr) - uses*: homeopathic remedy for relieving symptoms of bladder problems. *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. relieves burning sensation frequent urination & urgency.

Potassium Chloride 0.15% w/v & Glucose 5% w/v Solution for Infusion Airija - anglų - HPRA (Health Products Regulatory Authority)

potassium chloride 0.15% w/v & glucose 5% w/v solution for infusion

fresenius kabi limited - potassium chloride; glucose monohydrate - solution for infusion - 0.15 + 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates - blood substitutes and perfusion solutions; electrolytes with carbohydrates - prevention and treatment of potassium depletion and/or hypokalaemia in cases where supply of water and carbohydrates is required due to either restriction of the intake of fluids and electrolytes or depletion by normal routes

Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion Airija - anglų - HPRA (Health Products Regulatory Authority)

potassium chloride 0.3% w/v & glucose 5% w/v solution for infusion

fresenius kabi limited - potassium chloride; glucose monohydrate - solution for infusion - 0.3 + 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates - blood substitutes and perfusion solutions; electrolytes with carbohydrates - prevention and treatment of potassium depletion and/or hypokalaemia in cases where supply of water and carbohydrates is required due to either restriction of the intake of fluids and electrolytes or depletion by normal routes.

Synovis Supple Peri-Guard Pericardium with Apex Processing Singapūras - anglų - HSA (Health Sciences Authority)

synovis supple peri-guard pericardium with apex processing

baxter healthcare (asia) pte ltd - cardiovascular - intended for repair of pericardial structures and for use as a prosthesis for the surgical repair of soft tissue deficiencies, which include: defects of the abdominal and thoracis wall, hernias (including diaphragmatic, femoral, incisional, inguinal, lumbar, paracolostomy, scrotal, and umbilical) and intracardiac and great vessel repair.

DIGITALIS PURPUREA- foxglove granule Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

digitalis purpurea- foxglove granule

seroyal usa - digitalis (unii: f1t8qt9u8b) (digitalis - unii:f1t8qt9u8b) - digitalis 6 [hp_x] - indications helps to maintain a healthy cardiovascular system indications helps to maintain a healthy cardiovascular system directions adults: take five granules three times daily or as recommended by your healthcare practitioner. children: take three granules and follow adult directions.

ALISKIREN- aliskiren hemifumarate tablet, film coated Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aliskiren- aliskiren hemifumarate tablet, film coated

prasco laboratories - aliskiren hemifumarate (unii: c8a0p8g029) (aliskiren - unii:502fwn4q32) - aliskiren is indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age and older to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. there are no controlled trials demonstrating risk reduction with aliskiren. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection,